Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia

References

• BrunzellJDDavidsonMFurbergCDGoldbergRBHowardBVSteinJHLipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology FoundationDiabetes Care200831481182218375431
   PubMed Web of Science ®Google Scholar
• BodenWEHigh-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High – Density Lipoprotein Intervention TrialAm J Cardiol20008612A192222L
   Web of Science ®Google Scholar
• WilsonPWAbbottRDCastelliWPHigh density lipoprotein cholesterol and mortality. The Framingham Heart StudyArteriosclerosis1988867377413196218
   PubMedGoogle Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation19989718183718479603539
   PubMed Web of Science ®Google Scholar
• StamlerJDaviglusMLGarsideDBDyerARGreenlandPNeatonJDRelationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevityJAMA2000284331131810891962
   PubMed Web of Science ®Google Scholar
• GordonDJProbstfieldJLGarrisonRJNeatonJDCastelliWPKnokeJDHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesCirculation19897918152642759
   PubMed Web of Science ®Google Scholar
• AssmannGNoferJRAtheroprotective effects of high-density lipoproteinsAnnu Rev Med20035432134112414916
   PubMed Web of Science ®Google Scholar
• JeppesenJHeinHOSuadicaniPGyntelbergFTriglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male StudyCirculation19989711102910369531248
   PubMed Web of Science ®Google Scholar
• AssmannGSchulteHFunkeHvon EckardsteinAThe emergence of triglycerides as a significant independent risk factor in coronary artery diseaseEur Heart J199819Suppl MM8M149821011
   PubMedGoogle Scholar
• AustinMAHokansonJEEdwardsKLHypertriglyceridemia as a cardiovascular risk factorAm J Cardiol1998814A7B12B9462597
   PubMed Web of Science ®Google Scholar
• DurringtonPNTriglycerides are more important in atherosclerosis than epidemiology has suggestedAtherosclerosis1998141Suppl 1S57S629888644
   PubMedGoogle Scholar
• CarlsonLANicotinic acid: the broad-spectrum lipid drug. A 50th anniversary reviewJ Intern Med200525829411416018787
   PubMed Web of Science ®Google Scholar
• PaoliniJFBaysHEBallantyneCMDavidsonMPasternakRMaccubbinDExtended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factorsCardiol Clin200826454756019031552
   PubMed Web of Science ®Google Scholar
• BaysHEExtended-release niacin/lovastatin: the first combination product for dyslipidemiaExpert Rev Cardiovasc Ther20042448550115225109
   PubMedGoogle Scholar
• CannerPLBergeKGWengerNKStamlerJFriedmanLPrineasRJFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacinJ Am Coll Cardiol198686124512553782631
   PubMed Web of Science ®Google Scholar
• BlankenhornDHNessimSAJohnsonRLSanmarcoMEAzenSPCashin-HemphillLBeneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graftsJAMA198725723323332403295315
   PubMed Web of Science ®Google Scholar
• CarlsonLARosenhamerGReduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acidActa Med Scand198822354054183287837
   PubMed Web of Science ®Google Scholar
• Cashin-HemphillLMackWJPogodaJMSanmarcoMEAzenSPBlankenhornDHBeneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-upJAMA199026423301330172243429
   PubMed Web of Science ®Google Scholar
• KaneJPMalloyMJPortsTAPhillipsNRDiehlJCHavelRJRegression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimensJAMA199026423300730122243428
   PubMed Web of Science ®Google Scholar
• Clofibrate and niacin in coronary heart diseaseJAMA197523143603811088963
   PubMed Web of Science ®Google Scholar
• BaysHEDujovneCAMcGovernMEWhiteTEKashyapMLHutchesonAGComparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])Am J Cardiol200391666767212633795
   PubMed Web of Science ®Google Scholar
• GrundySMMokHYZechLBermanMInfluence of nicotinic acid on metabolism of cholesterol and triglycerides in manJ Lipid Res198122124367217784
   PubMed Web of Science ®Google Scholar
• IllingworthDRSteinEAMitchelYBDujovneCAFrostPHKnoppRHComparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trialArch Intern Med199415414158615958031206
   PubMedGoogle Scholar
• ProbstfieldJLHunninghakeDBNicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physicianArch Intern Med199415414155715598031204
   PubMedGoogle Scholar
• KamannaVSKashyapMLNicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?Am J Cardiol200710011 AS53S6118047854
   PubMed Web of Science ®Google Scholar
• ChesneyCMElamMBHerdJADavisKBGargRHunninghakeDEffect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT)Am Heart J2000140463163611011338
   PubMed Web of Science ®Google Scholar
• GanjiSHQinSZhangLKamannaVSKashyapMLNiacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cellsAtherosclerosis20092021687518550065
   PubMed Web of Science ®Google Scholar
• BaysHEMaccubbinDMeehanAGKuznetsovaOMitchelYBPaoliniJFBlood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patientsClin Ther200931111512219243712
   PubMed Web of Science ®Google Scholar
• BaysHERaderDJDoes nicotinic acid (niacin) lower blood pressure?Int J Clin Pract200963115115919054161
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJLeeJKGraceKAArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation2004110233512351715537681
   PubMed Web of Science ®Google Scholar
• TaylorAJLeeHJSullenbergerLEThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Curr Med Res Opin200622112243225017076985
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitAFisherLDCheungMCMorseJSSimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med2001345221583159211757504
   PubMed Web of Science ®Google Scholar
• BrownGAlbersJJFisherLDSchaeferSMLinJTKaplanCRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med199032319128912982215615
   PubMed Web of Science ®Google Scholar
• TaylorAJVillinesTCStanekEJDevinePJGriffenLMillerMExtended-release niacin or ezetimibe and carotid intima-media thicknessN Engl J Med200926;361222113212219915217
   PubMed Web of Science ®Google Scholar
• GuytonJRBaysHESafety considerations with niacin therapy.[see comment]Am J Cardiol2007996A22312231C
   Web of Science ®Google Scholar
• Kamal-BahlSWatsonDJAmbegaonkarBMPatients’ experiences of niacin-induced flushing in clinical practice: a structured telephone interviewClin Ther200931113014019243714
   PubMed Web of Science ®Google Scholar
• Kamal-BahlSJBurkeTWatsonDWentworthCDiscontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practiceAm J Cardiol200799453053417293198
   PubMed Web of Science ®Google Scholar
• Van HeckenADepreMDe LepeleireIThachCOeyenMVan EffenJThe effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteersEur J Clin Pharmacol200763213514117200838
   PubMed Web of Science ®Google Scholar
• LaiEWenningLACrumleyTMDe LepeleireILiuFde HoonJNPharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonistClin Pharmacol Ther200883684084717882161
   PubMed Web of Science ®Google Scholar
• MaccubbinDBaysHEOlssonAGElinoffVElisAMitchelYLipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaInt J Clin Pract200862121959197019166443
   PubMed Web of Science ®Google Scholar
• PaoliniJFMitchelYBReyesRKherULaiEWatsonDJEffects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemiaAm J Cardiol2008101562563018308010
   PubMed Web of Science ®Google Scholar
• Kamal-BahlSJBurkeTAWatsonDJWentworthCEDosage, titration, and gaps in treatment with extended release niacin in clinical practiceCurr Med Res Opin20082461817182118485268
   PubMed Web of Science ®Google Scholar
• GleimGLiuNThompson-BellSJohnson-LevonasABallantyneCMPasternakRCLipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin in patients with dyslipidemiaCirculation2007116II_127 (abstract 683).
   Web of Science ®Google Scholar
• BaysHEBallantyneCMWhat’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flushCurr Opin Lipidol20092046747619779335
   PubMed Web of Science ®Google Scholar
• NorquistJMWatsonDJYuQPaoliniJFMcQuarrieKSantanelloNCValidation of a questionnaire to assess niacin-induced cutaneous flushingCurr Med Res Opin20072371549156017559750
   PubMed Web of Science ®Google Scholar
• DishyVLiuFEbelDLAtieeGJRoyaltyJReilleySEffects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptomsJ Clin Pharmacol200949441642219246721
   PubMed Web of Science ®Google Scholar
• PaoliniJFMitchelYBReyesRThompson-BellSYuQLaiEMeasuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trialInt J Clin Pract200862689690418410350
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLMcGovernMETullochBRKendallDMFitz-PatrickDEfficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trialArch Intern Med2002162141568157612123399
   PubMedGoogle Scholar
• BallantyneCMDavidsonMHMcKenneyJKellerLHBajorunasDRKarasRHComparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)Am J Cardiol2008101101428143618471454
   PubMed Web of Science ®Google Scholar
• CapuzziDMGuytonJRMorganJMGoldbergACKreisbergRABruscoOAEfficacy and safety of an extended-release niacin (Niaspan): a long-term studyAm J Cardiol1998discussion 85U86U8212A74U81U
   Web of Science ®Google Scholar
• GoldbergAAlagonaPJrCapuzziDMGuytonJMorganJMRodgersJMultiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemiaAm J Cardiol20008591100110510781759
   PubMed Web of Science ®Google Scholar
• GuytonJRBlazingMAHagarJKashyapMLKnoppRHMcKenneyJMExtended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study GroupArch Intern Med200016081177118410789612
   PubMedGoogle Scholar
• KashyapMLMcGovernMEBerraKGuytonJRKwiterovichPOHarperWLLong-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemiaAm J Cardiol200289667267811897208
   PubMed Web of Science ®Google Scholar
• VogtAKassnerUHostalekUSteinhagen-ThiessenENAUTILUS Study GEvaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS studyCurr Med ResOpin2006222417425
   PubMed Web of Science ®Google Scholar
• CannerPLFurbergCDTerrinMLMcGovernMEBenefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200595225425715642562
   PubMed Web of Science ®Google Scholar
• PasternakRCKolmanBSUnstable myocardial ischemia after the initiation of niacin therapyAm J Cardiol19916799049062011995
   PubMed Web of Science ®Google Scholar